OakChart

Edesa Biotech Inc

EDSAHealthcare·Biotechnology·Canada·Nano·NASD·Nov 11 • 3:11 PM ET

2.13+0.11 (5.44%)
2026-11-11 21:12 CET
Market cap
27.29 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-14.10 USD m
Free cash flow, TTM
-8.93 USD m
EPS diluted, TTM
-1.69
P/E
-
Compare

Price

EDSA against its 20, 50 and 200-day averages
2050200miss
5.0010.0015.0042.3M84.6MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26EDSAclose 2.1320-day 2.5050-day 3.39200-day 5.692.13

89.5% under the 52-week high of 20.32 on 1 May 2026. 52-week low 0.72 on 20 Feb 2026. Last 15 sessions, 112.4% high to low

Volume 0.62× normal · the line is the 50-bar volume average

Profile

EDSA
52-week range, 7% of the way up
0.7220.32

Edesa Biotech, Inc. is a biopharmaceutical company, which focuses on acquisition, development, and commercialization of drug candidates for medical dermatology and respiratory diseases. Its clinical studies include EB05 for Acute Respiratory Distress Syndrome (ARDS), EB07 for systemic sclerosis (SSc), EB01 for chronic Allergic Contact Dermatitis (ACD), and EB06 for vitiligo. The company was founded by Pardeep Nijhawan on June 12, 2007 and is headquartered in Markham, Canada.

Employees17
IPOJun 21, 2010
Beta1.27
ATR, 14d0.38
Rel volume0.62
Short float1.35%
Insider own13.48%
Inst own42.50%

Snapshot

6 groups

Valuation

Index-
Market Cap28.77M
Enterprise Value26.85M
Income-14.10M
Sales0.00M
Book/sh0.04
Cash/sh0.76
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees17
IPOJun 21, 2010

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B51.42
P/C2.79
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio2.76
Current Ratio2.76
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortNo / Yes

Earnings

EPS (ttm)-1.69
EPS next Y-2.07
EPS next Q-0.58
EPS this Y-56.43%
EPS next Y-4.03%
EPS next 5Y-17.31%
EPS past 3/5Y-6.32% -11.35%
Sales past 3/5Y- -
EPS Y/Y TTM-27.34%
Sales Y/Y TTM-
EPS Q/Q-140.99%
Sales Q/Q-
EarningsAug 13 AMC
EPS/Sales Surpr.-37.93% -

Ownership

Insider Own13.48%
Insider Trans0.00%
Inst Own42.50%
Inst Trans7.99%
ROA-102.46%
ROE-122.93%
ROIC-160.05%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-14.92%
SMA50-37.24%
SMA200-62.56%
Trades-

Technical

Shs Outstand13.51M
Shs Float11.69M
Short Float1.35%
Short Ratio0.11
Short Interest0.16M
52W High20.32 -89.52%
52W Low0.72 195.82%
Volatility23.44% 12.70%
ATR (14)0.38
RSI (14)34.88
Beta1.27
Rel Volume0.62
Avg Volume1.39M
Volume763,865

Performance

Perf Week-1.85%
Perf Month-25.14%
Perf Quarter-60.78%
Perf Half Y-86.02%
Perf YTD49.99%
Perf Year17.03%
Perf 3Y-21.11%
Perf 5Y-95.68%
Perf 10Y-99.64%
Recom1.00
Target Price16.33
Prev Close2.02
Price2.13
Change %5.44%

Peers

Mkt cap
TickerCompanyMkt cap
MESOMesoblast Ltd ADR1.78B
ALDXAldeyra Therapeutics Inc40.86M
INCYIncyte Corp24.89B
XBITXBiotech Inc59.76M
ACRSAclaris Therapeutics Inc689.96M
VRCAVerrica Pharmaceuticals Inc67.00M
ARQTArcutis Biotherapeutics Inc3.54B
CTSOCytosorbents Corp17.40M
VCREVicore Pharma Holding AB ADR321.59M
SVRASavara Inc1.11B

Insider trading

9 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Brooks Michael JPresidentFeb 26 '26Buy1.572,0003,140226,870Mar 11 05:02 PM
Nijhawan PardeepChief Executive OfficerMar 10 '26Buy6.601,0006,599628,813Mar 10 05:02 PM
Nijhawan PardeepChief Executive OfficerMar 05 '26Buy3.9010,00039,000402,702Mar 06 05:01 PM
Nijhawan PardeepChief Executive OfficerMar 04 '26Buy4.2610,00042,560392,702Mar 05 05:01 PM
Nijhawan PardeepChief Executive OfficerMar 03 '26Buy3.6310,00036,300382,702Mar 04 05:01 PM
Nijhawan PardeepChief Executive OfficerMar 02 '26Buy2.002,0004,000627,813Mar 03 05:00 PM
Nijhawan PardeepChief Executive OfficerMar 02 '26Buy2.281,0002,280372,702Mar 03 05:00 PM
Nijhawan PardeepChief Executive OfficerFeb 27 '26Buy2.2230,00066,696371,702Mar 02 05:05 PM
Nijhawan PardeepChief Executive OfficerFeb 26 '26Buy1.5820,57132,480615,797Mar 02 05:05 PM

Held by

AUM
TickerCompanyAUM
VXFVanguard Extended Market Index ETFAUM: 30.47B

News

latest 14 of 200
  • Edesa Biotech Signs Japan Licensing Agreement With Kyorin for Paridiprubart Worth Up to $146 Million (InvestorsHub) +16.36%
  • Edesa Biotech Announces Agreement with KYORIN Pharmaceutical to Develop and Commercialize Paridiprubart in Japan (GlobeNewswire)
  • Edesa Biotech to Present at Guggenheim Healthcare Innovation Conference (GlobeNewswire)
  • Edesa Biotech Announces FDA IND Clearance for Phase 2 Vitiligo Study (GlobeNewswire)
  • Edesa Biotech Announces Pricing of $25.0 Million Public Offering (GlobeNewswire) -17.22%
  • Edesa Biotech Announces Proposed Public Offering (GlobeNewswire)
  • Edesa Biotech Reports Fiscal 3rd Quarter 2026 Results (GlobeNewswire)
  • Edesa Biotech Announces $3.5 Million Private Placement of Common Shares Led by CEO and Healthcare-Focused Investors (GlobeNewswire) +8.45%
  • Edesa Biotech Reports Positive Exploratory Data for Paridiprubart in Patients with Acute Kidney Injury (GlobeNewswire) -22.99%
  • Edesa Biotech to Present New Data on Paridiprubart in Acute Kidney Injury at European Nephrology Conference (GlobeNewswire) +32.78%
  • Edesa Biotech Reports Fiscal 2nd Quarter 2026 Results (GlobeNewswire) -10.68%
  • Edesa Biotech Invited for Oral Showcase at Respiratory Innovation Summit (GlobeNewswire) +6.12%
  • Edesa Biotech Advances Vitiligo Program for Planned Mid-2026 Enrollment (GlobeNewswire) -10.81%
  • Edesa Biotech Reports Additional Positive Results from Phase 3 Paridiprubart Study (GlobeNewswire) +67.96%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-08-13-0.600-0.435-0.6000.000.002
2026Q22026-05-14-0.490-0.260-0.4940.000.002
2026Q12026-02-13-0.280-0.525-0.2820.000.002
2025Q42025-12-12-0.365-0.267-0.3160.000.003
2025Q32025-08-08-0.250-0.263-0.2490.000.003
2025Q22025-05-14-0.300-0.420-0.3000.000.001
2025Q12025-02-14-0.480-0.310-0.4840.000.001
2024Q42024-12-13-0.290-0.540-0.2960.000.002
2024Q32024-08-09-0.520-0.580-0.5180.000.002
2024Q22024-05-10-0.580-0.693-0.5830.000.003
2024Q12024-02-09-0.540-1.210-0.5370.000.002
2023Q42023-12-15-0.575-0.703-0.0800.000.003
2023Q32023-08-11-0.700-1.097-0.0970.000.003
2023Q22023-05-11-0.840-1.213-0.1170.000.003
2023Q12023-02-10-0.910-1.237-0.1270.000.003
2022Q42022-12-16-1.050-2.193-0.1690.000.003

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2016FY-23.940-23.940-23.9401.271.15
2020FY-5.180-5.145-0.7390.330.26
2021FY-7.700-8.377-1.1050.000.00
2022FY-7.350-9.147-1.0530.000.00
2023FY-2.930-3.100-0.4190.000.00
2024FY-1.930-2.155-1.9300.000.00
2025FY-1.270-1.170-1.2700.000.00
2026FY--1.987--0.00
2027FY--2.067--0.00
2028FY--2.050--23.26
2029FY--2.370--70.47
2030FY--1.260--112.05

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-08-142000.000.000.00
2026Q4S2026-06-262000.000.000.00
2026Q4S2026-05-151000.000.000.00
2026Q4S2026-02-161000.000.000.00
2026Q4S2026-02-081000.000.000.00
2026Q4S2025-12-152000.000.000.00
2026Q4S2025-11-111000.000.000.00
2026Q4S2025-11-101000.000.000.00
2026Q4S2025-11-091000.000.000.00
2026Q4S2025-11-081000.000.000.00
2026Q4S2025-11-071000.000.000.00
2026Q4S2025-11-061000.000.000.00
2026Q4S2025-11-051000.000.000.00
2026Q4S2025-11-041000.000.000.00

Estimate history

EPS, annual-20.58-10.537-0.735-0.739-1.105-1.053-0.419-1.93-1.266-1.6918
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.518-0.296-0.484-0.3-0.249-0.316-0.282-0.494-0.6
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual0.2280.2120.5480.329000000
Period201720182019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual0.250.8887.5049.61513.29516.66221.5283.2477.1429.633
Period201720182019202020212022202320242025MRQ
Shares, quarterly3.2473.2473.4687.0237.0237.1428.3348.8869.633
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.000.000.000.000.000.330.550.21
Cost of Goods Sold Incl. D&A0.100.120.190.180.120.120.080.140.45
Gross Profit-0.10-0.12-0.19-0.18-0.12-0.120.250.41-0.23
Selling, General and Administrative Excl. Other14.537.796.839.0418.2523.566.654.194.84
Research and Development9.083.672.884.7913.3417.953.331.462.09
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-14.63-7.91-7.01-9.22-18.37-23.68-6.40-3.78-5.08
Interest Expense0.000.000.000.000.000.000.000.000.00
Unusual Expense-0.52-0.78-0.70-0.58-0.78-10.340.00--
Net Income Before Taxes-14.10-7.18-6.17-8.37-17.55-13.34-6.36-3.70-5.04
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-14.10-7.19-6.17-8.37-17.55-13.34-6.36-3.70-5.04
Net Income From Continuing Operations-14.10-7.19-6.17-8.37-17.55-13.34-6.36-3.70-5.04
Net Income-14.10-7.19-6.17-8.37-17.55-13.34-6.36-3.70-5.04
EPS (Recurring)-1.61-1.36-2.08-0.44-1.09-1.70-0.74-0.74-10.54
EPS (Basic, Before Extraordinaries)-1.69-1.27-1.93-0.42-1.05-1.10-0.74-0.74-10.54
EPS (Diluted)-1.69-1.27-1.93-0.42-1.05-1.10-0.74-0.74-10.54
EBITDA-14.53-7.79-6.83-9.04-18.25-23.56-6.34-3.77-4.89
Non-Operating Income (Expense)0.00-0.060.150.270.04-0.000.040.070.04
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.540.580.420.921.922.350.440.050.11
Price To Sales Ratio------211.2557.2718.83
Gross Margin------77.1475.35-110.21
Operating Margin-------1,946.72-689.30-2,397.11
Net Margin-------1,935.59-675.82-2,378.56
Shares Outstanding9.637.143.2521.5316.6613.309.627.500.89
Market Capitalization27.2927.2914.4592.31107.45686.84543.1638.7451.87

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.030.030.030.030.030.020.040.04
Gross Profit-0.03-0.03-0.03-0.03-0.03-0.02-0.04-0.04
Selling, General and Administrative Excl. Other5.494.272.322.441.881.611.860.96
Research and Development3.962.771.121.230.940.481.020.10
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-5.52-4.30-2.34-2.47-1.90-1.64-1.90-1.00
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense-0.11-0.07-0.10-0.25-0.18-0.05-0.30-0.04
Net Income Before Taxes-5.41-4.22-2.25-2.23-1.75-1.59-1.62-0.96
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-5.41-4.22-2.25-2.23-1.75-1.59-1.62-0.96
Net Income From Continuing Operations-5.41-4.22-2.25-2.23-1.75-1.59-1.62-0.96
Net Income-5.41-4.22-2.25-2.23-1.75-1.59-1.62-0.96
EPS (Recurring)-0.61-0.50-0.29-0.34-0.27-0.31-0.55-0.30
EPS (Basic, Before Extraordinaries)-0.60-0.49-0.28-0.32-0.25-0.30-0.48-0.30
EPS (Diluted)-0.60-0.49-0.28-0.32-0.25-0.30-0.48-0.30
EBITDA-5.49-4.27-2.32-2.44-1.88-1.61-1.86-0.96
Non-Operating Income (Expense)0.000.01-0.01-0.01-0.03-0.00-0.020.01
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.430.380.320.400.140.050.080.07
Shares Outstanding9.638.898.337.147.027.023.473.25
Market Capitalization27.2943.6611.8317.3814.2617.065.8314.45

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments10.791.045.367.097.847.215.0310.306.57
Short Term Receivables0.640.270.631.263.300.090.220.040.00
Inventories0.000.000.000.000.000.000.000.220.07
Other Current Assets0.080.370.450.750.950.800.400.090.12
Total Current Assets11.511.686.449.0912.098.105.6410.666.76
Net Property, Plant & Equipment0.000.020.100.030.110.170.071.060.88
Total Investments and Advances0.000.000.000.000.000.000.000.050.07
Intangible Assets1.982.082.182.282.382.480.000.000.00
Deferred Tax Assets0.130.130.23------
Other Assets0.040.040.170.170.000.000.000.020.02
Total Assets13.663.949.1211.5814.5810.765.7211.787.72
Short Term Debt Incl. Current Port. of LT Debt0.000.020.070.020.080.070.000.000.00
Accounts Payable0.000.000.002.121.381.460.420.490.32
Other Current Liabilities1.081.811.75-0.000.000.000.040.000.00
Total Current Liabilities1.081.831.822.141.461.530.460.490.32
Long Term Debt0.000.000.020.000.020.090.000.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities0.130.130.23------
Other Liabilities0.000.000.000.040.050.030.000.000.00
Total Liabilities1.211.962.072.181.531.650.460.490.32
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value9.260.000.000.000.002.480.000.000.00
Common Equity3.191.987.059.3913.066.635.2611.297.40
Total Shareholders Equity12.451.987.059.3913.069.115.2611.297.40
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity12.451.987.059.3913.069.115.2611.297.40
Total Liabilities & Stockholders Equity13.663.949.1211.5814.5810.765.7211.787.72
Book Value Per Share0.450.610.330.560.980.690.7012.7029.54
Tangible Book Value Per Share0.17-0.030.230.430.800.430.7012.7029.54
Full-Time Employees171616161612102528
Price to Book Ratio48.775.0411.7611.4452.6081.914.684.199.72
Return on Assets-81.65-94.46-80.92-134.16-105.28-77.24-42.32-51.68-48.70
Return on Equity-99.57-136.66-101.88-156.34-120.39-88.61-44.76-53.93-51.04
Return on Invested Capital-57.71-311.44-118.47-186.86-102.02-69.16-70.44-44.65-67.99
Quick Ratio10.670.913.534.258.295.3012.2321.1420.85
Current Ratio10.670.913.534.258.295.3012.2321.6021.06

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-14.13-7.19-6.17-8.37-17.55-13.34-6.36-2.78-5.04
Depreciation0.100.120.190.180.120.120.060.000.19
Other Funds (Non Cash)1.840.730.521.256.323.200.600.030.22
Funds from Operations-12.19-6.34-5.46-6.94-11.12-10.03-5.71-2.74-4.63
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital3.25-0.990.570.31-1.16-3.640.72-2.110.01
Cash from Operating Activities-8.93-7.32-4.89-6.64-12.28-13.66-4.99-4.85-4.62
Capital Expenditures0.000.000.000.00-0.01-0.01-0.03-0.01-0.38
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.056.43-
Purchase or Sale of Investments0.000.000.000.000.000.000.000.00-4.08
Purchase of Investments0.000.000.000.000.000.00-0.500.00-9.08
Sale Or Maturity of Investments0.000.000.000.000.000.000.500.005.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities0.000.000.000.00-0.01-0.010.026.42-4.47
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock6.9917.030.624.8311.6314.177.060.008.77
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock6.9917.030.624.8311.6314.177.060.008.77
Proceedsfrom Stock Options-9.417.770.624.06-0.33-0.193.830.004.12
Issuance or Reduction of Debt, Net0.000.00-0.030.000.000.000.030.000.00
Change in Long Term Debt0.000.00-0.030.000.000.000.030.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.030.000.00
Reduction of Long Term Debt0.000.00-0.030.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities6.9917.030.594.8311.6314.177.090.008.77
Exchange Rate Effect-0.100.05-0.030.08-0.090.120.060.09-0.04
Net Change in Cash-2.059.75-4.32-1.73-0.750.632.181.66-0.35
Free Cash Flow-8.93-7.32-4.89-6.64-12.28-13.67-4.99-4.85-5.00
Preferred Dividends (Cash Flow)--0.000.000.000.00-0.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments10.3310.0012.0510.7912.3613.90
Short Term Receivables0.230.220.430.640.290.38
Inventories0.000.000.000.000.000.00
Other Current Assets0.220.200.230.080.110.11
Total Current Assets10.7810.4212.7211.5112.7614.39
Net Property, Plant & Equipment0.000.000.000.000.000.00
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets1.901.931.951.982.002.03
Deferred Tax Assets---0.13--
Other Assets0.040.040.040.040.040.04
Total Assets12.7212.3814.7113.6614.8016.45
Short Term Debt Incl. Current Port. of LT Debt0.000.000.000.000.000.00
Accounts Payable0.000.000.000.000.000.00
Other Current Liabilities3.912.190.761.080.670.91
Total Current Liabilities3.912.190.761.080.670.91
Long Term Debt0.000.000.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities---0.13--
Other Liabilities0.000.000.000.000.000.00
Total Liabilities3.912.190.761.210.670.91
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value8.418.379.309.269.229.19
Common Equity0.401.824.663.194.916.35
Total Shareholders Equity8.8110.2013.9512.4514.1315.54
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity8.8110.2013.9512.4514.1315.54
Total Liabilities & Stockholders Equity12.7212.3814.7113.6614.8016.45
Book Value Per Share0.040.210.560.450.700.90
Tangible Book Value Per Share-0.16-0.010.320.170.410.62
Full-Time Employees---17--
Price to Book Ratio48.779.363.183.532.246.60
Return on Assets-102.46-72.43-82.82-81.65-59.10-50.92
Return on Equity-122.93-81.16-96.38-99.57-69.64-58.78
Return on Invested Capital-61.37-41.37-16.11-17.90-12.38-10.23
Quick Ratio2.764.7616.8210.6718.9715.73
Current Ratio2.764.7616.8210.6718.9715.73

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-5.35-4.27-2.25-2.26-1.86-1.55
Depreciation0.030.030.030.030.030.02
Other Funds (Non Cash)0.540.490.400.410.180.06
Funds from Operations-4.78-3.75-1.82-1.83-1.65-1.46
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital1.741.70-0.260.08-0.18-0.87
Cash from Operating Activities-3.04-2.05-2.09-1.75-1.83-2.33
Capital Expenditures0.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.000.000.000.000.000.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.00---0.00-
Change in Capital Stock3.410.023.360.200.4414.58
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock3.410.023.360.200.4414.58
Proceedsfrom Stock Options-3.580.023.36-9.200.4414.58
Issuance or Reduction of Debt, Net0.000.000.000.000.02-0.02
Change in Long Term Debt0.000.000.000.000.02-0.02
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.02-0.02
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities3.410.023.360.200.4714.56
Exchange Rate Effect-0.04-0.02-0.01-0.040.17-0.06
Net Change in Cash0.34-2.051.26-1.59-1.2012.17
Free Cash Flow-3.04-2.05-2.09-1.75-1.83-2.33

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-301.35%0.2M11.7M57.28K
2026-10-151.38%0.2M11.7M63.25K
2026-09-301.86%0.2M11.0M64.47K
2026-09-151.99%0.2M11.0M82.12K
2026-08-312.24%0.2M11.0M126.93K
2026-08-142.67%0.2M7.8M167.74K
2026-07-312.82%0.2M7.7M223.48K
2026-07-153.68%0.3M7.7M502.56K
2026-06-303.69%0.3M7.7M532.59K
2026-06-153.72%0.3M7.7M783.03K
2026-05-293.29%0.2M7.3M2.09M
2026-05-152.86%0.2M7.7M4.57M
2026-04-306.79%0.5M7.6M4.60M
2026-04-153.76%0.3M7.1M4.40M
2026-03-315.44%0.4M7.3M4.36M
2026-03-138.28%0.6M7.3M4.07M
2026-02-2719.36%1.4M7.3M2.64M
2026-02-130.21%0.0M7.3M62.43K
2026-01-300.39%0.0M7.3M56.33K
2026-01-150.23%0.0M6.2M313.96K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-098-KCurrent report2026-11-08SEC
2026-11-054Statement of changes in beneficial ownership of securities2026-11-04SEC
2026-11-04SCHEDULE 13G/ASEC
2026-10-294Statement of changes in beneficial ownership of securities2026-10-28SEC
2026-10-238-KCurrent report2026-10-23SEC
2026-10-158-KCurrent report2026-10-15SEC
2026-10-064Statement of changes in beneficial ownership of securities2026-10-05SEC
2026-09-014Statement of changes in beneficial ownership of securities2026-09-01SEC
2026-08-26SCHEDULE 13GSEC
2026-08-25SCHEDULE 13D/ASEC
2026-08-25SCHEDULE 13D/ASEC
2026-08-208-KCurrent report2026-08-19SEC
2026-08-20424B5SEC
2026-08-19424B5SEC
2026-08-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-138-KCurrent report2026-08-13SEC
2026-08-044Statement of changes in beneficial ownership of securities2026-08-03SEC
2026-07-13EFFECTEffectiveness filing by commission orderSEC
2026-07-13424B3SEC
2026-07-024Statement of changes in beneficial ownership of securities2026-07-02SEC
2026-07-02S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-06-26DNotice of sales of securities on Form D (Regulation D)SEC
2026-06-18SCHEDULE 13GSEC
2026-06-16SCHEDULE 13D/ASEC
2026-06-164Statement of changes in beneficial ownership of securities2026-06-16SEC
2026-06-118-KCurrent report2026-06-10SEC
2026-06-058-KCurrent report2026-06-05SEC
2026-06-014Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-05-294Statement of changes in beneficial ownership of securities2026-05-27SEC
2026-05-294Statement of changes in beneficial ownership of securities2026-05-27SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-03130.74K600
2026-02102.32K300
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
Velan Capital Investment Management LP9.31%
Rubric Capital Management LP7.53%
PERCEPTIVE ADVISORS LLC6.33%
MILLENNIUM MANAGEMENT LLC6.32%
Stonepine Capital Management, LLC5.13%
Boxer Capital Management, LLC2.31%
VANGUARD CAPITAL MANAGEMENT LLC0.92%
JANE STREET GROUP, LLC0.81%
GEODE CAPITAL MANAGEMENT, LLC0.56%
VANGUARD FIDUCIARY TRUST CO0.44%

Funds

Fund% owned
VANGUARD EXTENDED MARKET INDEX FUND0.79%
Fidelity Extended Market Index Fund0.26%
Fidelity Total Market Index Fund0.10%
Fidelity Series Total Market Index Fund0.09%
Fidelity Nasdaq Composite Index Fund0.04%
Blackstone Alternative Multi-Strategy Fund0.00%

OakChart. EDSA. Cached 15 minutes.

Some panels did not load: ratings.